Who is sponsoring NCT04932798?

NCT04932798 is sponsored by Montreal Heart Institute.

What drugs are being tested in NCT04932798?

Interventions in NCT04932798: Resting ECG (if first visit is done on site only), 24-hour ambulatory electrocardiographic monitoring (Holter) (if first visit done on site only), 3-month AF detection monitoring using the Apple Watch.

What condition does NCT04932798 study?

NCT04932798 studies Genetic Predisposition, Atrial Fibrillation.

Is NCT04932798 still recruiting?

NCT04932798 is currently status unknown. Last updated 1 September 2022.

Last reviewed 2022-09-01 · How we verify

NCT04932798: GeneAF

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Genetic Risk-Based Atrial Fibrillation Screening (GeneAF Study)

Status unknown Last updated 1 September 2022

What this trial tests

trial testing Resting ECG (if first visit is done on site only) in Genetic Predisposition in 726 participants. Status unknown.

Timeline

1 June 2021

Primary endpoint
10 January 2026

10 January 2026

Quick facts

Lead sponsor	Montreal Heart Institute
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	726
Start date	1 June 2021
Primary completion	10 January 2026
Estimated completion	10 January 2026
Sites	1 location across Canada

Drugs / interventions tested

Resting ECG (if first visit is done on site only)
24-hour ambulatory electrocardiographic monitoring (Holter) (if first visit done on site only)
3-month AF detection monitoring using the Apple Watch

Conditions studied

Genetic Predisposition — all drugs for Genetic Predisposition →
Atrial Fibrillation — all drugs for Atrial Fibrillation →

Sponsor

Montreal Heart Institute

Who can join

18 and older, any sex, with Genetic Predisposition or Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

AF is the most common sustained arrhythmia in adults and its prevalence increases with advancing age. In this study, we aim to determine whether the published genome-wide polygenic scores for atrial fibrillation (GPSAF) can facilitate AF screening by accurately discriminating between patients with low and high risk for AF. All included patients are participating in the MHI biobank, an ongoing funded institutional DNA bank and clinical registry approved by the research ethics board where included patients consent for future genetic research. The study will compare AF detection rate using a 3 months near continuous monitoring in individuals with a high GPSAF with matched individuals from the bottom GPSAF.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Atrial fibrillation: epidemiology, screening and digital health.
Linz D, Gawalko M, Betz K, Hendriks JM, et al · · 2024 · cited 230× · PMID 38362546 · DOI 10.1016/j.lanepe.2023.100786

Verify or expand the search:

Other recruiting trials for Genetic Predisposition

Currently open trials in the same condition.

NCT06089421 — Genetic Information Assistant in Telegenetics · NA · recruiting
NCT06441942 — Prospective Multicenter Registry of Gender, Diversity and Inclusion (GEDI) of Women With Acute Coronary Syndrome · recruiting
NCT06554288 — Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral Palsy · Phase 1 · recruiting
NCT06446271 — Biomarkers in SCOTland CardiomyopatHy Registry (Bio-SCOTCH) · recruiting
NCT06377033 — Using the EHR to Advance Genomic Medicine Across a Diverse Health System · NA · recruiting

Other Montreal Heart Institute trials

Trials by the same sponsor.

NCT07524335 — Aspirin in Subclinical Coronary Artery Disease: A Pilot Randomised Controlled Trial · Phase 3 · not yet recruiting
NCT07257198 — Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone · Phase 3 · recruiting
NCT07391358 — DAPT Strategy in HBR Patients Undergoing Complex PCI Following ACS: Second-Phase Beta Testing of a Patients Decision Aid · NA · not yet recruiting
NCT05450328 — Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass Separation · Phase 2 · not yet recruiting
NCT07144722 — Prehabilitation Program for Patients Awaiting Elective Heart Surgery at Increased Risk of Postoperative Complications: F · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04932798 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Montreal Heart Institute
Last refreshed: 1 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04932798.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing